Sanofi CEO, Paul Hudson, proceeds in a reduction of the members of the organization’s executive committee, from 14 to 10, showing the door to four senior employees; Ameet Nathwani, chief medical and digital officer; Dieter Weinand, EVP of primary Care; Dominique Carouge, EVP of business transformation; and Kathleen Tregoning, EVP of external affairs.
The reshape in the company’s management was announced by the CEO during a Q4 2019 earnings call, and Sanofi confirmed the names of the executives leaving to us, after Bloomberg reported about it first.
During the earning’s call, the company’s CEO commented that “[...] We wanted to allocate more of our central expertise into our business units and increase the accountability,” adding that “there was some personal impact that is structural.”
Sanofi also provided us with an outline of the structure of the new executive committee, in which the roles of heads of external affairs, business transformation, strategy, primary care, and China & emerging markets have been removed.
Following Bayer’s example of focusing on digitalization, Sanofi’s CEO also announced that the management reshaping will include a split between the titles of chief medical officer and chief digital officer, with two different executives taking over these roles.
“I think we are a little bit behind in our agenda on the digital understanding and language capability internally,” said Hudson, and added that the role will have a ‘bias’ towards helping the company improve its user experience and data science management internally, in the ‘short- to medium-term’.